Applications and challenges of multivalent recombinant vaccines

References

• Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11:Suppl S5 - 11; http://dx.doi.org/10.1038/nm1209; PMID: 15812490
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54:1615 - 7; http://dx.doi.org/10.1093/cid/cis238; PMID: 22437237
   PubMed Web of Science ®Google Scholar
• Girard MP, Plotkin SA. HIV vaccine development at the turn of the 21st century. Curr Opin HIV AIDS 2012; 7:4 - 9; http://dx.doi.org/10.1097/COH.0b013e32834ddc96; PMID: 22156840
   PubMed Web of Science ®Google Scholar
• Johnston MI, Fauci AS. An HIV vaccine--challenges and prospects. N Engl J Med 2008; 359:888 - 90; http://dx.doi.org/10.1056/NEJMp0806162; PMID: 18753644
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Harty JT, Todryk SM. Viral vector vaccines make memory T cells against malaria. Immunology 2007; 121:158 - 65; http://dx.doi.org/10.1111/j.1365-2567.2006.02552.x; PMID: 17462077
   PubMed Web of Science ®Google Scholar
• Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 2006; 87:2135 - 43; http://dx.doi.org/10.1099/vir.0.81956-0; PMID: 16847108
   PubMed Web of Science ®Google Scholar
• Glück R, Burri KG, Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2005; 2:395 - 400; http://dx.doi.org/10.2174/156720105774370302; PMID: 16305442
   PubMedGoogle Scholar
• Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 2005; 18:317 - 26; http://dx.doi.org/10.1089/vim.2005.18.317; PMID: 16035943
   PubMed Web of Science ®Google Scholar
• Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162:171 - 82; http://dx.doi.org/10.1016/j.jbiotec.2012.08.012; PMID: 22981627
   PubMed Web of Science ®Google Scholar
• Zeltins A. Construction and Characterization of Virus-Like Particles. Rev Mol Biotechnol 2012; In Press
   Web of Science ®Google Scholar
• Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006; 24:4062 - 81; http://dx.doi.org/10.1016/j.vaccine.2006.02.031; PMID: 16530298
   PubMed Web of Science ®Google Scholar
• Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 2010; 11:1193 - 201; http://dx.doi.org/10.1208/s12249-010-9471-3; PMID: 20676947
   PubMed Web of Science ®Google Scholar
• Elena Gómez C, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 2012; 8:1192 - 207; http://dx.doi.org/10.4161/hv.20778; PMID: 22906946
   PubMed Web of Science ®Google Scholar
• Lynch A, Meyers AE, Williamson AL, Rybicki EP. Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media. Virol J 2012; 9:210; http://dx.doi.org/10.1186/1743-422X-9-210; PMID: 22988963
   PubMed Web of Science ®Google Scholar
• Sauter SL, Rahman A, Muralidhar G. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. Curr HIV Res 2005; 3:157 - 81; http://dx.doi.org/10.2174/1570162053506900; PMID: 15853721
   PubMed Web of Science ®Google Scholar
• Billeter MA, Naim HY, Udem SA. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 2009; 329:129 - 62; http://dx.doi.org/10.1007/978-3-540-70523-9_7; PMID: 19198565
   PubMed Web of Science ®Google Scholar
• Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6:255 - 66; http://dx.doi.org/10.1586/14760584.6.2.255; PMID: 17408374
   PubMed Web of Science ®Google Scholar
• Spielhofer P, Bächi T, Fehr T, Christiansen G, Cattaneo R, Kaelin K, et al. Chimeric measles viruses with a foreign envelope. J Virol 1998; 72:2150 - 9; PMID: 9499071
   PubMed Web of Science ®Google Scholar
• Mebatsion T, Conzelmann KK. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci U S A 1996; 93:11366 - 70; http://dx.doi.org/10.1073/pnas.93.21.11366; PMID: 8876141
   PubMed Web of Science ®Google Scholar
• Mebatsion T, Finke S, Weiland F, Conzelmann KKA. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997; 90:841 - 7; http://dx.doi.org/10.1016/S0092-8674(00)80349-9; PMID: 9298896
   PubMed Web of Science ®Google Scholar
• Schnell MJ. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol Lett 2001; 200:123 - 9; http://dx.doi.org/10.1111/j.1574-6968.2001.tb10703.x; PMID: 11425463
   PubMed Web of Science ®Google Scholar
• Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, et al. Attenuated measles virus as a vaccine vector. Vaccine 2007; 25:2974 - 83; http://dx.doi.org/10.1016/j.vaccine.2007.01.064; PMID: 17303293
   PubMed Web of Science ®Google Scholar
• Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, et al. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One 2011; 6:e14813; http://dx.doi.org/10.1371/journal.pone.0014813; PMID: 21625584
   PubMed Web of Science ®Google Scholar
• Knuchel MC, Marty RR, Azzouz Morin TN, Ilter O, Zuniga A, Naim HY. Relevance of a pre-existing measles immunity prior immunization with a recombinant measles vector. Hum Vaccin Immunother 2012; In Press
   Web of Science ®Google Scholar
• Wang Z, Hangartner L, Cornu TI, Martin LR, Zuniga A, Billeter MA, et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 2001; 19:2329 - 36; http://dx.doi.org/10.1016/S0264-410X(00)00523-5; PMID: 11257357
   PubMed Web of Science ®Google Scholar
• Zuniga A, Liniger M, Azzouz Morin TN, Marty RR, Wiegand M, Ilter O, et al. Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother 2012; In Press
   Web of Science ®Google Scholar
• Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009; 27:3299 - 305; http://dx.doi.org/10.1016/j.vaccine.2009.01.057; PMID: 19200842
   PubMed Web of Science ®Google Scholar
• Lee EM, Chung HK, Livesay J, Suschak J, Finke L, Hudacik L, et al. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J Virol Methods 2010; 163:287 - 94; http://dx.doi.org/10.1016/j.jviromet.2009.10.012; PMID: 19878696
   PubMed Web of Science ®Google Scholar
• Watkins DI. HIV vaccine development. Top HIV Med 2010; 18:35 - 6; PMID: 20516522
   PubMedGoogle Scholar
• Bolton DL, Santra S, Swett-Tapia C, Custers J, Song K, Balachandran H, et al. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine 2012; 30:5991 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.06.029; PMID: 22732429
   PubMed Web of Science ®Google Scholar
• McEnery R, Kresge KJ. First Evidence of Efficacy from Large-Scale HIV Vaccine Trial Results from a trial in Thailand show that the combination of two vaccine candidates provides some protection against HIV infection. VAX, 2009; Vol. 07, No. 09
   Google Scholar